PMADS

Id:	acc0001
Group:	1sens
Protein:	Ku70
Gene Symbol:	XRCC6
Protein Id:	P12956
Protein Name:	XRCC6_HUMAN
PTM:	acetylation
Site:	unclear
Site Sequence:
Disease Category:	Cancer
Disease:	Lung Cancer
Disease Subtype:	NSCLC
Disease Cellline:	H358
Disease Info:
Drug:	gefitinib
Drug Info:	Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Effect:	promote
Effect Info:	Amphiregulin promotes the resistance of non - small cell lung cancer cells to gefitinib by down - regulating the acetylation of Ku70.
Note:
Score:	5.0
Pubmed(PMID):	19826407
Sentence Index:	19826407_0
Sentence:	Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.

Sequence & Structure:

MSGWESYYKTEGDEEAEEEQEENLEASGDYKYSGRDSLIFLVDASKAMFESQSEDELTPFDMSIQCIQSVYISKIISSDRDLLAVVFYGTEKDKNSVNFKNIYVLQELDNPGAKRILELDQFKGQQGQKRFQDMMGHGSDYSLSEVLWVCANLFSDVQFKMSHKRIMLFTNEDNPHGNDSAKASRARTKAGDLRDTGIFLDLMHLKKPGGFDISLFYRDIISIAEDEDLRVHFEESSKLEDLLRKVRAKETRKRALSRLKLKLNKDIVISVGIYNLVQKALKPPPIKLYRETNEPVKTKTRTFNTSTGGLLLPSDTKRSQIYGSRQIILEKEETEELKRFDDPGLMLMGFKPLVLLKKHHYLRPSLFVYPEESLVIGSSTLFSALLIKCLEKEVAALCRYTPRRNIPPYFVALVPQEEELDDQKIQVTPPGFQLVFLPFADDKRKMPFTEKIMATPEQVGKMKAIVEKLRFTYRSDSFENPVLQQHFRNLEALALDLMEPEQAVDLTLPKVEAMNKRLGSLVDEFKELVYPPDYNPEGKVTKRKHDNEGSGSKRPKVEYSEEELKTHISKGTLGKFTVPMLKEACRAYGLKSGLKKQELLEALTKHFQD

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

XRCC6-Lys100
Cancer	Intensity
BRCA	-0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

XRCC6-Lys114
Cancer	Intensity
BRCA	-0.524
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-0.812
LUSC	-0.098
non_ccRCC
PDAC
UCEC	1.434

XRCC6-Lys123
Cancer	Intensity
BRCA	1.14
COAD
HGSC
ccRCC
GBM	-0.408
HNSC
LUAD
LUSC	-0.731
non_ccRCC
PDAC
UCEC

XRCC6-Lys129
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC	0.707
non_ccRCC
PDAC
UCEC

XRCC6-Lys206
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	-0.707
non_ccRCC
PDAC
UCEC

XRCC6-Lys282
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	-0.707
non_ccRCC
PDAC
UCEC	0.707

XRCC6-Lys287
Cancer	Intensity
BRCA	-1.078
COAD
HGSC
ccRCC
GBM	-0.364
HNSC
LUAD	1.558
LUSC	-0.425
non_ccRCC
PDAC
UCEC	0.309

XRCC6-Lys31
Cancer	Intensity
BRCA	0.526
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-1.492
LUSC	0.356
non_ccRCC
PDAC
UCEC	0.61

XRCC6-Lys317
Cancer	Intensity
BRCA	1.102
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-1.313
LUSC	-0.033
non_ccRCC
PDAC
UCEC	0.244

XRCC6-Lys331
Cancer	Intensity
BRCA	-0.542
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	1.237
LUSC	-1.031
non_ccRCC
PDAC
UCEC	0.337

XRCC6-Lys338
Cancer	Intensity
BRCA	-1.668
COAD
HGSC
ccRCC
GBM	0.405
HNSC
LUAD	1.01
LUSC	0.157
non_ccRCC
PDAC
UCEC	0.095

XRCC6-Lys392
Cancer	Intensity
BRCA	-0.899
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	1.077
non_ccRCC
PDAC
UCEC	-0.178

XRCC6-Lys461
Cancer	Intensity
BRCA	-1.509
COAD
HGSC
ccRCC
GBM	0.668
HNSC
LUAD	0.727
LUSC	-0.553
non_ccRCC
PDAC
UCEC	0.666

XRCC6-Lys463
Cancer	Intensity
BRCA	-0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	0.707
non_ccRCC
PDAC
UCEC

XRCC6-Lys516
Cancer	Intensity
BRCA	-1.335
COAD
HGSC
ccRCC
GBM	1.452
HNSC
LUAD	0.194
LUSC	-0.266
non_ccRCC
PDAC
UCEC	-0.046

XRCC6-Lys526
Cancer	Intensity
BRCA	1.223
COAD
HGSC
ccRCC
GBM	-0.791
HNSC
LUAD	0.411
LUSC	-0.842
non_ccRCC
PDAC
UCEC

XRCC6-Lys553
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	-0.707
non_ccRCC
PDAC
UCEC	0.707

XRCC6-Lys565
Cancer	Intensity
BRCA	1.467
COAD
HGSC
ccRCC
GBM	-0.358
HNSC
LUAD	0.22
LUSC	-1.292
non_ccRCC
PDAC
UCEC	-0.038

XRCC6-Lys570
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

XRCC6-Lys591
Cancer	Intensity
BRCA	-0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

XRCC6-Lys94
Cancer	Intensity
BRCA	-0.798
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-0.252
LUSC	1.46
non_ccRCC
PDAC
UCEC	-0.41

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
-	-	D	Hepatocellular carcinoma	Ubiquitination	32775003
-	-	U	Acute leukemia	Acetylation	30594243
-	-	U	Neuroblastoma	Acetylation	37957138

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb